Reported Earlier, Organogenesis Reports PuraPly AM Meets Primary Endpoint In Randomized Controlled Trial, Demonstrating Statistically Significant DFU Wound Closure At 12 Weeks
Benzinga Newsdesk 7 months ago
News
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Statistically significant (p<0.0477) DFU wound closure at 12 weeksRCT compared PuraPly®AM plus standard of care to standard of care aloneResults strengthen existing clinical evidence supporting future coverage
- Statistically significant (p<0.0477) DFU wound closure at 12 weeks
- RCT compared PuraPly®AM plus standard of care to standard of care alone
- Results strengthen existing clinical evidence supporting future coverage